Comment on 'Fingolimod to treat severe MS after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?' Maillart et al.
Multiple Sclerosis Centre of Catalonia, Neurology/Neuroimmunology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Carmen
C
Tur
Xavier
X
Montalban
D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D005260:Female; D000068876:Fingolimod Hydrochloride; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D000069442:Natalizumab; D011409:Propylene Glycols / Q000627:therapeutic use*; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D000069442:Natalizumab; D011409:Propylene Glycols; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine